Results 21 to 30 of about 5,781 (240)

COMPETE trial: Peptide receptor radionuclide therapy (PRRT) with 177Lu-edotreotide vs. everolimus in progressive GEP-NET [PDF]

Annals of Oncology, 2018
Marianne Pavel, Anja Rinke, Richard P. Baum   +2 more
openalex   +2 more sources

Combination Therapies with PRRT

Pharmaceuticals, 2021
Peptide receptor radionuclide therapy (PRRT) is a successful targeted radionuclide therapy in neuroendocrine tumors (NETs). However, complete responses remain elusive.
Anna Yordanova, Hojjat Ahmadzadehfar
doaj   +1 more source

SUN-331 Breaking New Ground: First Use of Peptide Receptor Radionuclide Therapy (Prrt) for Metastatic Medullary Thyroid Carcinoma in the Philippines - A Case Report [PDF]

J Endocr Soc
Eduardo Gonzáles, Laura Hay, Mea Glor L Tumambing, Eric C. Cruz   +3 more
europepmc   +3 more sources

Peptide receptor radionuclide therapy ( PRRT ) special issue [PDF]

Journal of Neuroendocrinology
Shaunak Navalkissoor, Robert P. Millar
openalex   +3 more sources

Perspective of molecular imaging and peptide receptor radionuclide therapy in pancreatic neuroendocrine tumors: where do we stand?

Journal of Pancreatology, 2023
The clinical use of nuclear medicine imaging and therapy in pancreatic neuroendocrine tumors has been greatly strengthened since the approval of 68Ga-DOTATATE and 177Lu-DOTATATE. However, many aspects are still under discussion.
Wenjia Zhu, Meixi Liu, Li Huo
doaj   +1 more source

Molecular Deconvolution of Circulating "Other Cells": A Reliable Predictive Marker of Therapy Response and Survival in Neuroendocrine Tumor Patients Receiving ¹⁷⁷Lu-DOTATATE PRRT. [PDF]

Cancer Med
ABSTRACT Purpose To assess the prognostic impact of pre‐treatment circulating other cells on treatment response and survival in neuroendocrine tumor (NET) patients receiving Peptide Receptor Radionuclide Therapy (PRRT) with 177Lu‐DOTATATE. Methods Healthy donors (HDs, n = 81) and NET patients (n = 137) were analyzed.
Padwal MK, Parghane RV, Basu S, Basu B.
europepmc   +2 more sources

Supportive Management of Patients with Advanced Pheochromocytomas and Paragangliomas Receiving PRRT

Current Oncology, 2021
Peptide receptor radionuclide therapy (PRRT) is used to treat patients with advanced malignant pheochromocytomas (PCCs) and paragangliomas (PGLs).
Erica S. Tsang, Gayle Funk, Janet Leung, Grace Kalish, Hagen F. Kennecke   +4 more
doaj   +1 more source

Long-term results of multimodal peptide receptor radionuclide therapy and fractionated external beam radiotherapy for treatment of advanced symptomatic meningioma

Clinical and Translational Radiation Oncology, 2020
Background: The combination of somatostatin receptor-directed peptide receptor radionuclide therapy (PRRT) in combination with external beam radiotherapy (EBRT) might prove a feasible treatment option in patients with advanced meningioma.
Philipp E. Hartrampf, Heribert Hänscheid, Olivia Kertels, Andreas Schirbel, Michael C. Kreissl, Michael Flentje, Reinhart A. Sweeney, Andreas K. Buck, Bülent Polat, Constantin Lapa   +9 more
doaj   +1 more source

Clinical Translational Research of Evans Blue Modified Peptides Used for Theranostics

Xiehe Yixue Zazhi, 2022
Peptide receptor radionuclide therapy (PRRT) specifically uses radiolabeled peptides as biological targeting vectors designed to deliver cytotoxic levels of radiation dose to cancer cells that overexpress specific receptors.
LIU Qingxing, CHEN Xiaoyuan, ZHU Zhaohui
doaj   +1 more source

The Challenge of Evaluating Response to Peptide Receptor Radionuclide Therapy in Gastroenteropancreatic Neuroendocrine Tumors: The Present and the Future

Diagnostics, 2020
The NETTER-1 study has proven peptide receptor radionuclide therapy (PRRT) to be one of the most effective therapeutic options for metastatic neuroendocrine tumors (NETs), improving progression-free survival and overall survival.
Virginia Liberini, Martin W. Huellner, Serena Grimaldi, Monica Finessi, Philippe Thuillier, Alfredo Muni, Riccardo E. Pellerito, Mauro G. Papotti, Alessandro Piovesan, Emanuela Arvat, Désirée Deandreis   +10 more
doaj   +1 more source